Difficulty: Medium
Average Score: 72%
Practice
Which doses of Aspirin may be more effective in inhibiting Thromboxane A2?
Correct answer
A
Rationale
The correct answer is option A) Low doses of Aspirin may be more effective in inhibiting Thromboxane A2. Aspirin works by irreversibly inhibiting the enzyme cyclooxygenase (COX), which is responsible for the production of Thromboxane A2, a potent platelet aggregator. Low doses of Aspirin selectively inhibit COX in platelets, leading to reduced Thromboxane A2 production without affecting the beneficial prostacyclin synthesis in endothelial cells. This selective inhibition at low doses allows for antiplatelet effects without significantly impacting other physiological processes.
Option B) High doses of Aspirin may not be as effective in inhibiting Thromboxane A2 because high doses can lead to non-selective COX inhibition, affecting prostacyclin synthesis in endothelial cells. Prostacyclin is a vasodilator and inhibitor of platelet aggregation that counteracts the effects of Thromboxane A2. Therefore, high doses of Aspirin may disrupt the balance between Thromboxane A2 and prostacyclin, reducing its efficacy in inhibiting platelet aggregation.
Option C) None is incorrect because Aspirin, even at low doses, has been shown to effectively inhibit Thromboxane A2 production in platelets through its COX inhibition mechanism.
Option D) All of the above is incorrect because only low doses of Aspirin are specifically effective in inhibiting Thromboxane A2 production while minimizing unwanted side effects associated with high doses. Understanding the appropriate dosing of Aspirin in the context of its pharmacological mechanism is crucial for optimizing its therapeutic benefits while minimizing potential risks in clinical practice.
Option B) High doses of Aspirin may not be as effective in inhibiting Thromboxane A2 because high doses can lead to non-selective COX inhibition, affecting prostacyclin synthesis in endothelial cells. Prostacyclin is a vasodilator and inhibitor of platelet aggregation that counteracts the effects of Thromboxane A2. Therefore, high doses of Aspirin may disrupt the balance between Thromboxane A2 and prostacyclin, reducing its efficacy in inhibiting platelet aggregation.
Option C) None is incorrect because Aspirin, even at low doses, has been shown to effectively inhibit Thromboxane A2 production in platelets through its COX inhibition mechanism.
Option D) All of the above is incorrect because only low doses of Aspirin are specifically effective in inhibiting Thromboxane A2 production while minimizing unwanted side effects associated with high doses. Understanding the appropriate dosing of Aspirin in the context of its pharmacological mechanism is crucial for optimizing its therapeutic benefits while minimizing potential risks in clinical practice.